1 篇报道
Ascletis reported positive preclinical data for its once-weekly oral peptide pipeline targeting obesity and metabolic disorders. The comprehensive portfolio covers four validated therapeutic targets with potential first-in-class fixed-dose combinations.
我们重视你的隐私. 我们使用必要的 Cookie 来保障网站运行;经你同意后,还会使用分析 Cookie 了解你的阅读偏好并改进网站。